Molecular Biology Reports

, Volume 38, Issue 4, pp 2589–2596 | Cite as

IL-6 −174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls

  • Bin Xu
  • Xiao-Bing Niu
  • Zi-Dun Wang
  • Wei Cheng
  • Na Tong
  • Yuan-Yuan Mi
  • Zhi-Chao Min
  • Jun Tao
  • Peng-Chao Li
  • Wei Zhang
  • Hong-Fei Wu
  • Zheng-Dong Zhang
  • Zeng-Jun Wang
  • Li-Xin Hua
  • Ning-Han Feng
  • Xin-Ru Wang


Interleukin-6 (IL-6) is a multifunctional cytokine involved in different physiologic and pathophysiologic processes and plays important roles in the etiology of cancer. The −174G>C polymorphism of the IL-6 gene influences IL-6 transcription and has been implicated in cancer risk. However, published data have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 29,377 cancer cases and 37,739 controls from 50 published case–control studies was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between −174G>C polymorphism and cancer risk. Overall meta-analysis indicated that no association was found between −174G>C genotypes and cancer risk. However, the positive association was found in bladder cancer (OR = 4.33, 95% CI: 1.93–9.71 for CC vs. GC, OR = 2.81, 95% CI: 1.39–5.68 for CC vs. GG, and OR = 2.19, 95% CI: 1.32–3.64 for CC vs. GG/GC), and among Asians (OR = 2.08, 95% CI: 1.07–4.06 for CC vs. GG, and OR = 2.20, 95% CI: 1.02–4.74 for CC vs. GG/GC) and Africans (OR = 1.61, 95% CI: 1.07–2.42 for GC vs. GG). This meta-analysis showed the evidence that the −174G>C of the IL-6 gene was a low-penetrance susceptibility gene for bladder cancer. Further larger, perferably prospective studies are needed to confirm this relationship.


IL-6 IL6 Polymorphism Cancer risk Meta-analysis Molecular epidemiology 



Odds ratio


Confidence interval





This study was supported by the Foundation of Key Medical Department of Jiangsu Province—Department of Urology of Jiangsu Province Hospital (XK17 200904), National Natural Science Foundation of China (NO. 30872575), Foundation of Key Medical Department of Jiangsu Province—Department of General Surgery of Jiangsu Province Hospital and National Eleventh-Five Science and Technology Support Program of China (No. 2006BAI03B12).

Supplementary material

11033_2010_399_MOESM1_ESM.doc (147 kb)
Supplementary material 1 (DOC 147 kb)


  1. 1.
    Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park), 16, 217-226, 229; Discussion 230–232Google Scholar
  2. 2.
    Samsami Dehaghani A, Shahriary K, Kashef MA, Naeimi S, Fattahi MJ, Mojtahedi Z, Ghaderi A (2009) Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep 36:2393–2397PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang L, Du C, Guo X, Yuan L, Niu W, Yu W, Er L, Wang S (2010) Interleukin-8–251A/T polymorphism and Helicobacter pylori infection influence risk for the development of gastric cardiac adenocarcinoma in a high-incidence area of China. Mol Biol Rep 37(8):3983–3989. doi: 10.1007/s11033-010-0057-7 PubMedCrossRefGoogle Scholar
  4. 4.
    Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. Faseb J 11:457–465PubMedGoogle Scholar
  5. 5.
    Phoa N, Epe B (2002) Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis 23:469–475PubMedCrossRefGoogle Scholar
  6. 6.
    Moore MA (2002) Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J Cell Biochem Suppl 38:29–38PubMedCrossRefGoogle Scholar
  7. 7.
    Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531–536PubMedCrossRefGoogle Scholar
  8. 8.
    Asschert JG, Vellenga E, Ruiters MH, de Vries EG (1999) Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 82:244–249PubMedCrossRefGoogle Scholar
  9. 9.
    Takeda K, Fujii N, Nitta Y, Sakihara H, Nakayama K, Rikiishi H, Kumagai K (1991) Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 82:1299–1308PubMedGoogle Scholar
  10. 10.
    DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B (2003) Interleukin-6–174G>C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051–8056PubMedGoogle Scholar
  11. 11.
    Ray A, LaForge KS, Sehgal PB (1990) On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10:5736–5746PubMedGoogle Scholar
  12. 12.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376PubMedCrossRefGoogle Scholar
  13. 13.
    Litovkin KV, Domenyuk VP, Bubnov VV, Zaporozhan VN (2007) Interleukin-6–174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 29:295–298PubMedGoogle Scholar
  14. 14.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  16. 16.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315:629–634PubMedGoogle Scholar
  17. 17.
    Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW, Bordin JO (2007) Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40:265–267PubMedCrossRefGoogle Scholar
  18. 18.
    Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560–3566PubMedGoogle Scholar
  19. 19.
    Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173PubMedCrossRefGoogle Scholar
  20. 20.
    Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E (2009) Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54:683–689PubMedCrossRefGoogle Scholar
  21. 21.
    Howell WM, Turner SJ, Theaker JM, Bateman AC (2003) Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30:409–414PubMedCrossRefGoogle Scholar
  22. 22.
    Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PR, White J, Jarrett RF (2005) Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin’s lymphoma. Br J Haematol 128:493–495PubMedCrossRefGoogle Scholar
  23. 23.
    Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L (2005) Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16:253–260PubMedGoogle Scholar
  24. 24.
    Vasku JA, Vasku A, Goldbergova M, Vasku V (2004) Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL). Clin Immunol 113:256–260PubMedCrossRefGoogle Scholar
  25. 25.
    Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A, Grimble R, Fearon K (2007) Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 14:329–339PubMedCrossRefGoogle Scholar
  26. 26.
    Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S (2007) IL-6–174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Exp Mol Pathol 83:474–479PubMedCrossRefGoogle Scholar
  27. 27.
    Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K, Lange A (2005) IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96:241–246PubMedCrossRefGoogle Scholar
  28. 28.
    Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Maciejewski JP (2007) Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 136:237–248PubMedCrossRefGoogle Scholar
  29. 29.
    Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 11:5718–5721PubMedCrossRefGoogle Scholar
  30. 30.
    Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465–469PubMedCrossRefGoogle Scholar
  31. 31.
    Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, Witteman J, Uitterlinden AG, Coebergh JW, Hofman A, Stricker BH, van Duijn CM (2006) Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol 21:373–376PubMedCrossRefGoogle Scholar
  32. 32.
    Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, Holm G, Yi Q (2000) Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109:39–45PubMedCrossRefGoogle Scholar
  33. 33.
    Cherel M, Campion L, Bezieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jezequel P (2009) Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Cytokine 47(3):214–223PubMedCrossRefGoogle Scholar
  34. 34.
    Vasku A, Vokurka J, Bienertova-Vasku J (2009) Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. Int J Colorectal Dis 24:289–294PubMedCrossRefGoogle Scholar
  35. 35.
    Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28:1728–1733PubMedGoogle Scholar
  36. 36.
    Kamangar F, Abnet CC, Hutchinson AA, Newschaffer CJ, Helzlsouer K, Shugart YY, Pietinen P, Dawsey SM, Albanes D, Virtamo J, Taylor PR (2006) Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 17:117–125PubMedCrossRefGoogle Scholar
  37. 37.
    Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165PubMedGoogle Scholar
  38. 38.
    Zhang Z, Liu W, Jia X, Gao Y, Hemminki K, Lindholm B (2004) Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta 342:137–143PubMedCrossRefGoogle Scholar
  39. 39.
    Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1–8PubMedCrossRefGoogle Scholar
  40. 40.
    Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235PubMedCrossRefGoogle Scholar
  41. 41.
    Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD (2007) IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18:1095–1105PubMedCrossRefGoogle Scholar
  42. 42.
    Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRefGoogle Scholar
  43. 43.
    Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188PubMedCrossRefGoogle Scholar
  44. 44.
    Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M, Gabbas A, Serpe R, Madeddu C, Scarpa A, Cocco P (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26:98–103PubMedCrossRefGoogle Scholar
  45. 45.
    Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131PubMedCrossRefGoogle Scholar
  46. 46.
    Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A (2007) Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28:427–434PubMedCrossRefGoogle Scholar
  47. 47.
    Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A (2008) Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639:89–100PubMedGoogle Scholar
  48. 48.
    Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617:138–146PubMedCrossRefGoogle Scholar
  49. 49.
    Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, Hallmans G, Hemminki K, Lenner P, Forsti A (2008) Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29:1202–1206PubMedCrossRefGoogle Scholar
  50. 50.
    Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101–4108PubMedCrossRefGoogle Scholar
  51. 51.
    Gatti LL, Burbano RR, Zambaldi-Tunes M, de-Labio RW, de Assumpcao PP, de Arruda Cardoso-Smith M, Marques-Payao SL (2007) Interleukin-6 polymorphisms, Helicobacter pylori infection in adult Brazilian patients with chronic gastritis and gastric adenocarcinoma. Arch Med Res 38:551–555PubMedCrossRefGoogle Scholar
  52. 52.
    Aladzsity I, Kovacs M, Semsei A, Falus A, Szilagyi A, Karadi I, Varga G, Fust G, Varkonyi J (2009) Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33:1570–1573PubMedCrossRefGoogle Scholar
  53. 53.
    Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Hatzakis A, Paraskevis D, Nieters A, Petridou ET (2009) Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 83:334–342PubMedCrossRefGoogle Scholar
  54. 54.
    Kesarwani P, Ahirwar DK, Mandhani A, Mittal RD (2008) Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 27:505–510PubMedCrossRefGoogle Scholar
  55. 55.
    Slattery ML, Wolff RK, Curtin K, Fitzpatrick F, Herrick J, Potter JD, Caan BJ, Samowitz WS (2009) Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res 660:12–21PubMedCrossRefGoogle Scholar
  56. 56.
    Festa F, Kumar R, Sanyal S, Unden B, Nordfors L, Lindholm B, Snellman E, Schalling M, Forsti A, Hemminki K (2005) Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res 574:105–111PubMedCrossRefGoogle Scholar
  57. 57.
    Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6–174G>C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11–16PubMedGoogle Scholar
  58. 58.
    Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746–5756PubMedCrossRefGoogle Scholar
  59. 59.
    Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423PubMedCrossRefGoogle Scholar
  60. 60.
    Ozgen AG, Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C (2009) The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32:491–494PubMedGoogle Scholar
  61. 61.
    Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 16:747–755PubMedCrossRefGoogle Scholar
  62. 62.
    Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, Giuliano AR, Byers T (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring) 16:339–347CrossRefGoogle Scholar
  63. 63.
    Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, Rothman N, Bernstein L, Hartge P, Morhbacher A, Coetzee SG, Salam MT, Wang W, Zadnick J, Ingles SA (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15:2285–2291PubMedCrossRefGoogle Scholar
  64. 64.
    Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW, Patsouris E (2006) Strong association of interleukin-6–174 > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21:246–250PubMedGoogle Scholar
  65. 65.
    Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214PubMedCrossRefGoogle Scholar
  66. 66.
    Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG (2010) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31:455–461PubMedCrossRefGoogle Scholar
  67. 67.
    Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, Minisini R, Pirisi M (2009) Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77:304–313PubMedCrossRefGoogle Scholar
  68. 68.
    Cacev T, Jokic M, Loncar B, Krizanac S, Kapitanovic S (2010) Interleukin-6–174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 29:177–182PubMedCrossRefGoogle Scholar
  69. 69.
    Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, Visvanathan K, Platz EA (2009) Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20:1739–1751PubMedCrossRefGoogle Scholar
  70. 70.
    Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753–756PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Bin Xu
    • 1
    • 2
  • Xiao-Bing Niu
    • 1
  • Zi-Dun Wang
    • 1
  • Wei Cheng
    • 1
  • Na Tong
    • 2
  • Yuan-Yuan Mi
    • 1
  • Zhi-Chao Min
    • 1
  • Jun Tao
    • 1
  • Peng-Chao Li
    • 1
  • Wei Zhang
    • 1
  • Hong-Fei Wu
    • 1
  • Zheng-Dong Zhang
    • 2
  • Zeng-Jun Wang
    • 1
  • Li-Xin Hua
    • 1
  • Ning-Han Feng
    • 1
  • Xin-Ru Wang
    • 3
  1. 1.Department of Urology, Laboratory of Reproductive MedicineFirst Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Department of Molecular and Genetic ToxicologyCancer Center of Nanjing Medical UniversityNanjingChina
  3. 3.Laboratory of Reproductive Medicine, Institute of ToxicologyNanjing Medical UniversityNanjingChina

Personalised recommendations